Effects of vedolizumab in patients with primary sclerosing cholangitis and inflammatory bowel diseases

Effects of vedolizumab in patients with primary sclerosing cholangitis and inflammatory bowel diseases

<p><strong>Background & Aims</strong> Gut-homing lymphocytes that express the integrin α4β7 and CCR9 might contribute to development of primary sclerosing cholangitis (PSC). Vedolizumab, which blocks the integrin α4β7, is used to treat patients with inflammatory bowel disea...

Descripció completa

Dades bibliogràfiques
Autors principals:	Lynch, K, Chapman, R, Keshav, S, Montano-Loza, A, Mason, A, Kremer, A, Vetter, M, De Krijger, M, Ponsioen, C, Trivedi, P, Hirschfield, G, Schramm, C, Liu, C, Bowlus, C, Estes, D, Pratt, D, Hedin, C, Bergquist, A, De Vries, A, Janneke Van Der Woude, C, Yu, L, Assis, D, Boyer, J, Ytting, H, Hallibasic, E, Trauner, M, Marschall, H, Daretti, L, Marzioni, M, Yimam, K, Perin, N, Floreani, A, Beretta-Piccoli, B, Rogers, J, International Primary Sclerosing Cholangitis Study Group (IPSCSG), Levy, C
Format:	Journal article
Idioma:	English
Publicat:	Elsevier 2019

Ítems similars

International experience of vedolizumab in primary sclerosing cholangitis and inflammatory bowel disease
per: Williamson, K, et al.
Publicat: (2018)

Vedolizumab for the treatment of chronic pouchitis
per: Travis, S, et al.
Publicat: (2023)

Fecal calprotectin is an early predictor of endoscopic response and histologic remission after the start of vedolizumab in inflammatory bowel disease
per: Renske W. M. Pauwels, et al.
Publicat: (2020-12-01)

Subcutaneous vedolizumab interval extension in inflammatory bowel disease patients: a case series
per: Suzanne I. Anjie, et al.
Publicat: (2024-02-01)

Vedolizumab: Potential Mechanisms of Action for Reducing Pathological Inflammation in Inflammatory Bowel Diseases
per: Matthew Luzentales-Simpson, et al.
Publicat: (2021-02-01)

P571 Vedolizumab (VDZ) real-world outcomes in ulcerative colitis (UC)
per: Pulusu, S, et al.
Publicat: (2018)

Patient considerations in the management of ulcerative colitis – role of vedolizumab
per: Kothari M, et al.
Publicat: (2015-08-01)

Vedolizumab for inflammatory bowel diseasesI
per: Igor L. Khalif, et al.
Publicat: (2018-08-01)

Vedolizumab in the treatment of inflammatory bowel diseases: whom and how?
per: A. O. Golovenko, et al.
Publicat: (2018-10-01)

Vedolizumab as a Potential Culprit in the Development of Ovarian Teratoma?
per: Judy A. Trieu, et al.
Publicat: (2017-12-01)

Vedolizumab-Induced Liver Injury
per: Miguel Mascarenhas Saraiva, et al.
Publicat: (2020-12-01)

Vedolizumab in paediatric Inflammatory Bowel Disease: A retrospective multi-centre experience From the paediatric IBD Porto Group of ESPGHAN
per: Ledder, O, et al.
Publicat: (2017)

Vedolizumab in pediatric inflammatory bowel disease: a retrospective multi-center experience from the Paediatric IBD Porto group of ESPGHAN
per: Ledder, O, et al.
Publicat: (2017)

Long-term outcomes and predictors of vedolizumab persistence in ulcerative colitis
per: Beatriz Gros, et al.
Publicat: (2024-07-01)

Validation of the prognostic value of histologic scoring systems in primary sclerosing cholangitis: An international cohort study.
per: de Vries, E, et al.
Publicat: (2016)

Vedolizumab in Inflammatory Bowel Disease: West versus East
per: Prasanta Debnath, et al.
Publicat: (2021-01-01)

Protocol for the development of a core outcome set for clinical trials in primary sclerosing cholangitis
per: Martine Walmsley, et al.
Publicat: (2024-06-01)

Post-marketing experience of vedolizumab: Pneumonia and other respiratory tract infections
per: Bhayat, F, et al.
Publicat: (2017)

Vedolizumab in Pediatric inflammatory bowel diseases: a retrospective multi-center experience from the paediatric IBD Porto group of ESPGHAN
per: Ledder, O, et al.
Publicat: (2017)

Incidence of pneumonia and other respiratory tract infections with vedolizumab treatment: clinical trial experience
per: Feagan, B, et al.
Publicat: (2017)

Clinical efficacy of vedolizumab for inflammatory bowel disease
per: Liu Sixue, Zhong Wa, Lin Ying, Xia Zhongsheng, Zhong Yingqiang
Publicat: (2022-10-01)

Acute Chest Pain as an Infusion Reaction to Vedolizumab
per: Asaf Levartovsky, et al.
Publicat: (2022-06-01)

Post-marketing safety experience of vedolizumab in older patients with inflammatory bowel disease
per: Travis, S, et al.
Publicat: (2018)

Respiratory tract infections in patients with inflammatory bowel disease: safety analyses from vedolizumab clinical trials
per: Feagan, BG, et al.
Publicat: (2018)

Vedolizumab does not increase risk of clostridium difficile infection in patients with inflammatory bowel disease using vedolizumab: A retrospective cohort study
per: Abdulaziz Saad Alshahrani, et al.
Publicat: (2023-09-01)

Impact on the budget of ONLS program of vedolizumab introduction for the treatment of inflammatory bowel disease
per: S. K. Zyryanov, et al.
Publicat: (2018-05-01)

Vedolizumab more likely to be discontinued than ustekinumab in anti-TNF-experienced patients with fistulizing Crohn’s disease
per: Kira L. Newman, et al.
Publicat: (2023-03-01)

Therapeutic Drug Monitoring of Vedolizumab in Inflammatory Bowel Disease Patients during Maintenance Treatment—TUMMY Study
per: Merve Sivridaş, et al.
Publicat: (2023-03-01)

Vedolizumab for perianal fistulizing Crohn’s disease: systematic review and meta-analysis
per: Fares Ayoub, et al.
Publicat: (2022-04-01)

Introducing vedolizumab to clinical practice: who, when and how?
per: Bryant, R, et al.
Publicat: (2015)

A product review of vedolizumab in inflammatory bowel disease
per: Robert Battat, et al.
Publicat: (2019-10-01)

Vedolizumab in the treatment of inflammatory bowel disease: evolving paradigms
per: Benjamin Crooks, et al.
Publicat: (2020-03-01)

Incidence of pneumonia and other respiratory tract infections with vedolizumab treatment for inflammatory bowel disease: clinical trial experience
per: Feagan, B, et al.
Publicat: (2017)

Evaluating Efficacy of Vedolizumab, Ustekinumab, and Golimumab in the Management of Inflammatory Bowel Disease and the Combined Role of Nutritional Therapy with Biologics: A Review
per: Shahed Kamal, et al.
Publicat: (2024-08-01)

Post-marketing experience of vedolizumab in inflammatory bowel disease: analysis of pneumonia and other respiratory tract infections
per: Bhayat, F, et al.
Publicat: (2017)

Systematic review: the safety of vedolizumab for the treatment of inflammatory bowel disease.
per: Bye, W, et al.
Publicat: (2017)

Vedolizumab in Crohn Disease genesis-sefh drug evaluation report
per: Jenifer González Chávez, et al.
Publicat: (2015-09-01)

Ustekinumab and Vedolizumab Dual Biologic Therapy in the Treatment of Crohn’s Disease
per: Eddie Y. Liu, et al.
Publicat: (2017-01-01)

Take vedolizumab home: transition from intravenous to subcutaneous treatment
per: Kaituo Huang, et al.
Publicat: (2024-05-01)

Acquired hemophilia associated with vedolizumab in a patient with hemorrhagic rectocolitis
per: Thomas Schiestel
Publicat: (2023-03-01)